UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number: 001-41661
JIN MEDICAL INTERNATIONAL LTD.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On October 10, 2024, Jin Medical International
Limited issued a press release entitled “JinMed New Manufacturing Facility Initiation at Chuzhou China”, a copy of which is
attached to this Form 6-K as Exhibit 99.1.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
JIN MEDICAL INTERNATIONAL LTD. |
|
|
|
Date: October 11, 2024 |
By: |
/s/ Erqi Wang |
|
|
Erqi Wang |
|
|
Chief Executive Officer |
2
Exhibit 99.1
Construction of JinMed’s New Facility
Begins in Chuzhou, China
Chuzhou City, China, Oct. 10, 2024 (GLOBE
NEWSWIRE) -- JIN MEDICAL INTERNATIONAL LTD. (the “Company” or “JinMed”) (NASDAQ: ZJYL), an industrial leader in
Assistive Technologies (“AT”), and a manufacturer and developer of wheelchairs and living aids products, today announced the
initiation of construction of JinMed’s new manufacturing facility at Chuzhou City, Anhui Province, China. JinMed (Anhui) Co., Ltd.,
a newly established subsidiary of JinMed, will be designated to operate the Chuzhou JinMed plant (the “New Facility”) which
is established as an internationally standardized, innovative, and high-end wheelchair and electric wheelchair manufacturing factory.
With higher-level production lines in place, more innovative high-quality products are expected to strengthen JinMed’s leadership
in the AT industry.
JinMed’s Chairman and Chief Executive
Officer, Mr. Wang Erqi, said that the commencement of the New Facility is another major milestone for JinMed. JinMed will utilize the
establishment of the New Facility as an opportunity to continue to uphold the goal of ” global technology for the benefit of mankind”,
further strengthen its leadership in the AT industry, and demonstrate the responsibility and commitment of JinMed.
The new Chuzhou facility is targeted to operate
in 2025. In addition to the expansion of capacity of JinMed’s current manual wheelchair lines, JinMed will also produce electric
wheelchairs and electric scooter specialty lines. Healthcare products such as micro hyperbaric chambers and scientific cosmetic products
will also be in production at the New Facility.
About Jin Medical International Ltd.
Founded in 2006 and headquartered at Changzhou,
Jiangsu Province of China, JinMed, designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities,
the elderlies, and for rehabilitation application. Currently, JinMed operates two manufacturing plants with approximately 230,000
square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. JinMed is establishing a new facility with 430,000
square feet at Chuzhou, Anhui Province, China. JinMed has more than 40 distributors in China and more than 20 international distributors.
The majority of JinMed’s wheelchair products, with more than 30 models, are sold to distributors in Japan and China, including Nissin
Medical Industries Co., Ltd, one of the largest medical device distributors in Japan. JinMed continuously deliver innovative wheelchair
products that are both lightweight and ergonomic. For more information, please visit: http://www.zhjmedical.com.
Forward-Looking Statement
This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning
plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,”
“believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that
do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations
discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the
following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business
development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand,
the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions,
and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S.
Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as
well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
ir@zhjmedical.com
Jin Medical (NASDAQ:ZJYL)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Jin Medical (NASDAQ:ZJYL)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024